Lets look at what the research actually shows
By adjusting the dose and watching how patients do, doctors can help them safely and effectively
[10] The first amylin analogue to reach the clinic, pramlintide, demonstrated that the pathway could be drugged, but native-style amylin analogues are short-acting and were used as multiple-daily injections, which limited their appeal for weight management
Semaglutide was on the market first, originally for diabetes type two, and then they found it does great for weight loss too, Paesano explains
Novo initially held an advantage over Lilly, as WEGOVY entered the market before Lillys competing drug, ZEPBOUND, and secured broader insurance coverage early on